Huakang Biomedical Holdings Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chunguang Zhang

Chief executive officer

CN¥689.0k

Total compensation

CEO salary percentage	44.7%
CEO tenure	6.8yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chunguang Zhang's remuneration changed compared to Huakang Biomedical Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CN¥6m
Sep 30 2023	n/a	n/a	-CN¥5m
Jun 30 2023	n/a	n/a	-CN¥4m
Mar 31 2023	n/a	n/a	-CN¥3m
Dec 31 2022	CN¥689k	CN¥308k	-CN¥3m
Sep 30 2022	n/a	n/a	-CN¥2m
Jun 30 2022	n/a	n/a	-CN¥3m
Mar 31 2022	n/a	n/a	-CN¥4m
Dec 31 2021	CN¥399k	CN¥271k	-CN¥4m
Sep 30 2021	n/a	n/a	-CN¥7m
Jun 30 2021	n/a	n/a	-CN¥8m
Mar 31 2021	n/a	n/a	-CN¥10m
Dec 31 2020	CN¥727k	CN¥250k	-CN¥12m
Sep 30 2020	n/a	n/a	-CN¥9m
Jun 30 2020	n/a	n/a	-CN¥7m
Mar 31 2020	n/a	n/a	-CN¥3m
Dec 31 2019	CN¥349k	CN¥227k	-CN¥284k
Sep 30 2019	n/a	n/a	-CN¥3m
Jun 30 2019	n/a	n/a	-CN¥2m
Mar 31 2019	n/a	n/a	-CN¥377k
Dec 31 2018	CN¥284k	CN¥234k	-CN¥459k
Dec 31 2017	CN¥243k	CN¥183k	-CN¥2m

Compensation vs Market: Chunguang's total compensation ($USD95.20K) is below average for companies of similar size in the Hong Kong market ($USD232.65K).

Compensation vs Earnings: Chunguang's compensation has increased whilst the company is unprofitable.

CEO

Chunguang Zhang (54 yo)

6.8yrs

Tenure

CN¥689,000

Compensation

Mr. Chunguang Zhang is Chief Executive officer at Huakang Biomedical Holdings Company Limited. Mr. Zhang is mainly responsible for business operations and the day-to-day management of Group. Mr. Zhang has...

Board Members

Name	Position	Tenure	Compensation	Ownership
Shuguang Zhang	Chairman of the Board	6.8yrs	CN¥621.00k	27.71% CN¥ 13.6m
Chunguang Zhang	CEO & Executive Director	6.8yrs	CN¥689.00k	no data
Lai Yin Poon	CFO, Compliance Officer & Executive Director	6.8yrs	CN¥959.00k	0.80% CN¥ 392.0k
Jiaming He	Executive Director	4.3yrs	CN¥464.00k	no data
Kin Sang Chan	Independent Non-Executive Director	5.5yrs	CN¥86.00k	no data
Faat Ting Cheng	Independent Non Executive Director	3.7yrs	CN¥86.00k	no data
Kwok Fai Chow	Independent Non-Executive Director	3.4yrs	CN¥86.00k	no data
Ching Chow	Independent Non-Executive Director	less than a year	no data	no data

4.9yrs

Average Tenure

52yo

Average Age

Experienced Board: 8622's board of directors are considered experienced (4.9 years average tenure).

Huakang Biomedical Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Chairman of the Board recently sold HK$815k worth of stock

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Recent updates

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age